Core Viewpoint - The company Shijiazhuang Pharmaceutical Group (02005) is experiencing a significant decline in expected profits for the fiscal year 2025, projecting a decrease of 45%-60% compared to the previous year's profit of 1.061 billion HKD [1] Group 1 - The company's stock price fell over 5%, currently trading at 2.66 HKD with a trading volume of 52.9044 million HKD [1] - The anticipated profit decline is primarily attributed to a lack of large-scale epidemics in 2025, which is expected to reduce the demand for intravenous infusions and other pharmaceuticals [1] - The expansion of various forms of volume-based procurement and intensified competition in both domestic and international markets are contributing to ongoing pricing pressures [1] Group 2 - The revenue from the injection of bromhexine hydrochloride ampoules is expected to decrease as it will no longer be sold through the national drug collection system [1]
港股异动 | 石四药集团(02005)午后跌超5% 预计2025年度纯利同比下降45%-60%